Lastly, with 25–30% of lung adenocarcinoma exhibiting a mutation within the PI3K-AKT-mTOR pathway [74,75], our model with a myristoylated p110α complements models with other metabolic mutations. This evidence concerns the gene AKT1 and lung adenocarcinoma.